<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2305233703
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SANDOSTATIN LAR 30MG VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OCTREOTIDE ACETATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        5227.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Novartis Pharmaceutical Manufacturing GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Novartis Pharmaceutical Manufacturing GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H01CB02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sandostatin LAR is a synthetic compound derived from somatostatin. Somatostatin is normally found in the human body, where it inhibits the release of certain hormones such as growth hormone. The advantages of Sandostatin LAR over somatostatin are that it is stronger and its effects last longer.</p><p>&nbsp;</p><p><strong>Sandostatin LAR is used</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat acromegaly,</p><p>Acromegaly is a condition where the body produces too much growth hormone. Normally, growth hormone controls growth of tissues, organs, and bones. Too much growth hormone leads to an increase in the size of bones and tissues, especially in the hands and feet. Sandostatin LAR markedly reduces the symptoms of acromegaly, which include headache, excessive perspiration, numbness of the hands and feet, tiredness, and joint pain. In most cases, the overproduction of growth hormone is caused by an enlargement in the pituitary gland (a pituitary adenoma); Sandostatin LAR treatment may reduce the size of the adenoma.</p><p>&nbsp;</p><p>Sandostatin LAR is used to treat people with acromegaly:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; when other types of treatment for acromegaly (surgery or radiotherapy) are not suitable or haven&rsquo;t worked;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after radiotherapy, to cover the interim period until the radiotherapy becomes fully effective.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to relieve symptoms associated with overproduction of some specific hormones and other related substances by the stomach, bowels or pancreas,</p><p>Overproduction of specific hormones and other related natural substances can be caused by some rare conditions of the stomach, bowels or pancreas. This upsets the natural hormonal balance of the body and results in a variety of symptoms, such as flushing, diarrhoea, low blood pressure, rash, and weight loss. Treatment with Sandostatin LAR helps to control these symptoms.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat neuroendocrine tumours located in the gut (e.g. appendix, small intestine or colon)</p><p>Neuroendocrine tumours are rare tumours which can be found in different parts of the body. Sandostatin LAR is also used to control the growth of these tumours, when they are located in the gut (e.g. appendix, small intestine or colon).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat pituitary tumours that produce too much thyroid‑stimulating hormone (TSH).</p><p>Too much thyroid‑stimulating hormone (TSH) leads to hyperthyroidism. Sandostatin LAR is used to treat people with pituitary tumours that produce too much thyroid‑stimulating hormone (TSH):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; when other types of treatment (surgery or radiotherapy) are not suitable or have not worked;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after radiotherapy, to cover the interim period until the radiotherapy becomes fully effective.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all instructions given to you by your doctor carefully. They may differ from the information contained in this leaflet.</p><p>&nbsp;</p><p>Read the following explanations before you use Sandostatin LAR.</p><p>&nbsp;</p><p><strong>a. Do not take Sandostatin LAR:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to octreotide or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p><strong>b. Take special care with Sandostatin LAR</strong></p><p>Talk to your doctor before using Sandostatin LAR:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you know that you have gallstones now, or have had them in the past or experience any complications like fever, chills, abdominal pain, or yellowing of your skin or eyes; tell your doctor, as prolonged use of Sandostatin LAR may result in gallstone formation. Your doctor may wish to check your gallbladder periodically.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you know that you have diabetes, as Sandostatin LAR can affect blood sugar levels. If you are diabetic, your sugar levels should be checked regularly.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of vitamin B12 deprivation your doctor may wish to check your vitamin B12 level periodically.</p><p>&nbsp;</p><p><strong>Test and checks</strong></p><p>&nbsp;</p><p>If you receive treatment with Sandostatin LAR over a long period of time, your doctor may wish to check your thyroid function periodically.</p><p>&nbsp;</p><p>Your doctor will check your liver function.</p><p>&nbsp;</p><p><strong>Children</strong></p><p>There is little experience with the use of Sandostatin LAR in children.</p><p>&nbsp;</p><p><strong>c.Taking other medicines, herbal or dietary supplements </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>You can generally continue taking other medicines while on Sandostatin LAR. However, certain medicines, such as cimetidine, ciclosporin, bromocriptine, quinidine and terfenadine have been reported to be affected by Sandostatin LAR.</p><p>&nbsp;</p><p>If you are taking a medicine to control your blood pressure (e.g. a beta blocker or a calcium channel blocker) or an agent to control fluid and electrolyte balance, your doctor may need to adjust the dosage.</p><p>&nbsp;</p><p>If you are diabetic, your doctor may need to adjust your insulin dosage.</p><p>&nbsp;</p><p><strong>e. Pregnancy and breast‑feeding</strong></p><p>If you are pregnant or breast‑feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p>Sandostatin LAR should only be used during pregnancy if clearly needed.</p><p>&nbsp;</p><p>Women of child‑bearing age should use an effective contraceptive method during treatment.</p><p>&nbsp;</p><p>Do not breast-feed while using Sandostatin LAR. It is not known whether Sandostatin LAR passes into breast milk.</p><p>&nbsp;</p><p><strong>f. Driving and using machines</strong></p><p>Sandostatin LAR has no or negligible effects on the ability to drive and use machines. However, some of the side effects you may experience while using Sandostatin LAR, such as headache and tiredness, may reduce your ability to drive and use machines safely.</p><p>&nbsp;</p><p><strong>g. Important information about some of the ingredients of Sandostatin LAR </strong></p><p><strong>&nbsp;</strong></p><p><strong>Sandostatin LAR contains sodium</strong></p><p>This medicine contains sodium less than 1&nbsp;mmol sodium (23&nbsp;mg) per vial, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sandostatin LAR must always be administered as an injection into the muscle of the buttocks. With repeated administration, the left and right buttock should be used alternately.</p><p>&nbsp;</p><p><strong>a. If you take more Sandostatin LAR than you should</strong></p><p>No life‑threatening reactions have been reported after overdose of Sandostatin LAR.</p><p>&nbsp;</p><p>The symptoms of overdose are: hot flushes, frequent urination, tiredness, depression, anxiety and lack of concentration.</p><p>&nbsp;</p><p>If you think that an overdose has happened and you experience such symptoms, tell your doctor straight away.</p><p>&nbsp;</p><p><strong>b. If you forget to take Sandostatin LAR</strong></p><p>If your injection is forgotten, it is recommended that you are given it as soon as it is remembered, and then continue as usual. It will not do any harm if a dose is a few days late, but you could get some temporary re-appearance of symptoms until you get back on schedule.</p><p>&nbsp;</p><p><strong>c. If you stop taking Sandostatin LAR</strong></p><p>If you interrupt your treatment with Sandostatin LAR your symptoms may come back. Therefore, do not stop using Sandostatin LAR unless your doctor tells you to.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Some side effects could be serious. Tell your doctor straight away if you get any of the following:</strong></p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gallstones, causing sudden back pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Too much sugar in the blood.</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Underactive thyroid gland (hypothyroidism) causing changes in heart rate, appetite or weight; tiredness, feeling cold, or swelling at the front of the neck.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in thyroid function tests.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the gallbladder (cholecystitis); symptoms may include pain in the upper right abdomen, fever, nausea, yellowing of the skin and eyes (jaundice).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Too little sugar in the blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impaired glucose tolerance.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow heart beat.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thirst, low urine output, dark urine, dry flushed skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast heart beat.</p><p>&nbsp;</p><p><strong>Other serious side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity (allergic) reactions including skin rash.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A type of an allergic reaction (anaphylaxis) which can cause difficulty in swallowing or breathing, swelling and tingling, possibly with a drop in blood pressure with dizziness or loss of consciousness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An inflammation of the pancreas gland (pancreatitis); symptoms may include sudden pain in the upper abdomen, nausea, vomiting, diarrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver inflammation (hepatitis); symptoms may include yellowing of the skin and eyes (jaundice), nausea, vomiting, loss of appetite, generally feeling unwell, itching, light‑coloured urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heart beat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of platelet count in blood; this could result in increased bleeding or bruising.</p><p>&nbsp;</p><p>Tell your doctor straight away if you notice any of the side effects above.</p><p>&nbsp;</p><p><strong>Other side effects:</strong></p><p>Tell your doctor, pharmacist or nurse if you notice any of the side effects listed below. They are usually mild and tend to disappear as treatment progresses.</p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flatulence (wind).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Local pain at the injection site.</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach discomfort after meal (dyspepsia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling of fullness in the stomach.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatty stools.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loose stools.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discolouration of faeces.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in liver function tests.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness.</p><p>&nbsp;</p><p>If you get any side effects, please tell your doctor, nurse or pharmacist.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leafletBy reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p><p>Store in a refrigerator (2&deg;C to 8&deg;C). Do not freeze.</p><p>Sandostatin LAR may be stored below 25&deg;C on the day of injection.</p><p>Do not store Sandostatin LAR after reconstitution (it must be used immediately).</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP.&nbsp; The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not use this medicine if you notice particles or a change of colour.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is octreotide<br />One vial contains 10&nbsp;mg, 20&nbsp;mg or 30&nbsp;mg octreotide (as octreotide acetate)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are<br />in powder (vial): poly(DL-lactide-co-glycolide) and mannitol (E421).<br />in solvent (prefilled syringe): carmellose sodium, mannitol (E421), poloxamer&nbsp;188, water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Unit packs containing one 6 mL glass vial with rubber stopper (bromobutyl rubber), sealed with an aluminium flip-off seal, containing powder for suspension for injection and one 3 mL colourless pre-filled glass syringe with front and plunger stopper (chlorobutyl rubber) with 2 mL solvent, co-packaged in a sealed blister tray with one vial adapter and one safety injection needle. 

	Not all pack sizes may be marketed
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 This leaflet was last approved by MHRA on 12/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">عقار ساندوستاتين إل إيه آر هو مُرَكَّب تخليقي مُشتَق من مادة السوماتوستاتين. تُوجَد مادة السوماتوستاتين بشكلٍ طبيعيٍّ في الجسم البشري، حيث تقوم بتثبيط إفراز بعض الهرمونات مثل هرمون النمو. المميزات التي يتفوق بها عقار ساندوستاتين إل إيه آر على سوماتوستاتين هي أن فعَّاليته أقوى وتأثيراته تستمر لفترة أطول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُستَخدَم عقار ساندوستاتين</strong> <strong>إل إيه آر</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج ضخامة الأطراف،</p><p dir="RTL">ضخامة الأطراف هي حالة ينتج فيه الجسم كمية أكثر مما يجب من هرمون النمو. عادةً يتحكم هرمون النمو في نمو الأنسجة والأعضاء والعظام. يُؤدي وجود كمية أكبر مما يجب من هرمون النمو إلى زيادة في حجم العظام والأنسجة، خاصةً في اليدين والقدمين. يقلل عقار ساندوستاتين إل إيه آر بشكل ملحوظ أعراض ضخامة الأطراف، والتي تتضمن الصداع، والتَّعرق الزَّائد، والتَّنميل في اليدين والقدمين، والتَّعب،&nbsp; وألم المفاصل. في أغلب الحالات، ينتج فرط إنتاج هرمون النمو بسبب وجود تضخُّم في الغدة النخامية (ورم في الغدة النخامية)؛ وقد يقلل العلاج بعقار ساندوستاتين إل ايه آر حجم الورم بالغدة النخامية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستَخدَم عقار ساندوستاتين إل إيه آر لعلاج الأشخاص المُصابين بضخامة الأطراف:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما تكون أنواع العلاج الأخرى (الجراحة أو العلاج الإشعاعي) غير مناسبة أو لم تُفلح؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد العلاج الإشعاعي، ليشمل الفترة المؤقتة التي يستغرقها العلاج الإشعاعي حتى يصبح فعَّالًا تمامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لتخفيف الأعراض الناتجة عن فرط إنتاج بعض الهرمونات المُحَددة وغيرها من المواد ذات الصلة بواسطة المعدة أو الأمعاء أو البنكرياس،</p><p dir="RTL">قد يكون فرط إنتاج هرمونات مُحَددة وغيرها من المواد الطبيعية ذات الصلة نتيجة بعض الحالات النَّادرة في المعدة أو الأمعاء أو البنكرياس. يُؤدي هذا إلى إخلال التَّوازن الهرموني الطبيعي بالجسم وينتج عنه مجموعة متنوعة من الأعراض، مثل: احمرار الجلد، والإسهال، وانخفاض ضغط الدَّم، والطفح الجلدي، وفقدان الوزن. يُساعِد العلاج بعقار ساندوستاتين إل إيه آر على التَّحكم في هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج الأورام العَصَبِيّة الصمَّاوِيّة في الأمعاء (على سبيل المثال: الزائدة أو الأمعاء الدقيقة أو القولون).</p><p dir="RTL">الأورام العَصَبِيَّة الصّمَّاوِيّة هي: أورام نادرة يُمكِن أن توجد في أجزاء مختلفة من الجسم. يُستَخدَم أيضًا عقار ساندوستاتين إل إيه آر للتحكم في نمو هذه الأورام، عندما توجد في الأمعاء (على سبيل المثال: الزَّائدة أو الأمعاء الدقيقة أو القولون).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج أورام الغدة النخامية التي تنتج كمية أكثر مما يجب من الهرمون المنبه للغدة الدَّرقية (TSH).</p><p dir="RTL">قد يُؤدي وجود كمية أكثر مما يجب من الهرمون المنبه للغدة الدَّرقية إلى الإصابة بفرط نشاط الغدة الدَّرقية. يُستَخدَم عقار ساندوستاتين إل إيه آر لعلاج الأشخاص المُصابين بأورام الغدة النخامية التي تنتج كمية أكثر مما يجب من الهرمون المنبه للغدة الدرقية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما تكون أنواع العلاج الأخرى (الجراحة أو العلاج الإشعاعي) غير مناسبة أو لم تُفلح؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد العلاج الإشعاعي، ليشمل الفترة المؤقتة التي يستغرقها العلاج الإشعاعي حتى يصبح فعَّالًا تمامًا.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع بعناية جميع التَّعليمات التي يعطيها لك طبيبك، والتي قد تختلف عن المعلومات العامة الواردة في هذه النَّشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اقرأ الإيضاحات التَّالية قبل استخدام عقار ساندوستاتين إل إيه آر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ. موانع استعمال عقار ساندوستاتين إل إيه آر:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه أوكتريوتايد أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب. الاحتياطات عند استعمال عقار ساندوستاتين إل إيه آر</strong></p><p dir="RTL">تحدَّث إلى طبيبك قبل استخدام عقار ساندوستاتين إل إيه آر:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعلم أنك مُصاب بحصى المرارة في الوقت الحالي، أو أُصِبت بها في الماضي أو تعاني من أي مضاعفات مثل الحمى أو القشعريرة أو آلام البطن أو اصفرار الجلد أو العينين ، فأخبِر طبيبك؛ إذ قد يُؤدي استخدام عقار ساندوستاتين إل إيه آر إلى تكوين حصى المرارة. قد يرغب طبيبك في إجراء فحص للمرارة لديك بصفة دورية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا علمت أنك مُصاب بمرض السُّكَّرِي؛ لأنَّ عقار ساندوستاتين إل إيه آر يُمكِن أن يُؤثر على مستويات السُّكَّر بالدَّم. إذا كنت تُعاني من مرض السُّكَّرِي، يجب أن يتم فحص مستويات السكر لديك بشكل منتظم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ مَرَضي بالإصابة بنقص فيتامين ب12 فقد يرغب طبيبك في فحص مستوى فيتامين ب12 لديك بصفة دورية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاختبار والفحوصات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تلقيت العلاج بعقار ساندوستاتين إل إيه آر على مدار فترة زمنية طويلة، فقد يرغب طبيبك في فحص وظائف الغدة الدَّرقية لديك بصفة دورية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقوم طبيبك بفحص وظائف الكبد لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">هناك معلومات محدودة بشأن استخدام عقار ساندوستاتين إل إيه آر في الأطفال.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. التداخلات الدوائية من أخذ هذا المستحضر مع أدوية أخرى أو أعشاب أو مكملات غذائية </strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُمكِنك بشكلٍ عام مواصلة تناوُل أدوية أخرى أثناء العلاج بعقار ساندوستاتين إل إيه آر. مع ذلك، تم الإبلاغ عن تأثر بعض الأدوية بعقار ساندوستاتين إل إيه آر، مثل: سيميتيدين، وسيكلوسبورين، وبروموكريبتين، وكينيدين، وتيرفينادين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول دواء للتَّحكم في ضغط الدَّم لديك (على سبيل المثال: أحد حاصرات بيتا أو أحد حاصرات قناة الكالسيوم) أو دواء للتَّحكم في توازن السّوائل والإليكتروليتات، فقد يحتاج طبيبك إلى تعديل الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت مُصابًا بمرض السُّكَّرِي، فقد يحتاج طبيبك إلى تعديل جرعة الأنسولين الخاصة بك.</p><p dir="RTL"><strong>د. الحمل والرضاعة </strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ حامل أو تخططين لذلك، فاستشيري طبيبك قبل تناوُل هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يُستَخدَم عقار ساندوستاتين إل إيه آر أثناء الحَمْل فقط إذا كانت هناك حاجة مُلِحّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب على السيدات ممن لديهن القدرة على الحَمْل استخدام وسيلة فعَّالة لمنع الحَمْل أثناء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تمارسي الرضاعة الطبيعية أثناء استخدام عقار ساندوستاتين إل إيه آر. من غير المعروف ما إذا كان عقار ساندوستاتين إل إيه آر يمر إلى لبن الأم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. تأثير </strong><strong>ساندوستاتين إل إيه آر</strong><strong> على القيادة واستخدام الآلات </strong></p><p dir="RTL">ليس لعقار ساندوستاتين إل إيه آر تأثير (أو هناك تأثير لا يكاد يذكر) في القدرة على القيادة واستخدام الآلات. مع ذلك، فإنَّ بعض الآثار الجانبية التي قد تعاني منها أثناء استخدام عقار ساندوستاتين، مثل: الصداع والتَّعب، قد تحد من قدرتك على القيادة واستخدام الآلات بأمان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و.معلومات هامة حول بعض مكونات </strong><strong>عقار ساندوستاتين</strong> <strong>إل إيه آر</strong></p><p dir="RTL"><strong>يحتوي دواء ساندوستاتين على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مللي مول صوديوم (23 مجم) لكل أمبولة / قنينة، ذلك بالقول انه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن يُعطى عقار ساندوستاتين إل إيه آر دائمًا في هيئة حَقْن عضلي في الأرداف. مع تكرار الإعطاء، يجب استخدام الردفين الأيسر والأيمن بالتناوب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من عقار ساندوستاتين إل إيه آر</strong></p><p dir="RTL">لم يتم الإبلاغ عن تفاعلات مُهَددة للحياة بعد تلقي جرعة زائدة من عقار ساندوستاتين إل إيه آر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أعراض الجرعة الزَّائدة هي: هبات ساخنة، وتبوُّل متكرر، وتعب، واكتئاب، وقلق، وفقدان التركيز.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعتقد أنك قد تلقيت جرعة زائدة وواجهت هذه الأعراض، فأخبر طبيبك فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة من عقار ساندوستاتين إل إيه آر</strong></p><p dir="RTL">إذا تم إغفال أحد مرات الحَقْن، يُوصى بأن يُعطى لك بمجرد تَذَكُّرِه، ومن ثم مواصلة العلاج كالمعتاد. لن يحدث أي ضرر إذا تأخرت في تلقي جرعة لمدة عدة أيام، ولكن قد تتعرض لتكرار الظهور المؤقت لبعض الأعراض حتى الرجوع إلى الانتظام في الجدول المحدد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول عقار ساندوستاتين إل إيه آر</strong></p><p dir="RTL">إذا أوقفت علاجك بعقار ساندوستاتين إل إيه آر فقد تعود الأعراض في الظهور لديك مرة أخرى. لذلك، لا تتوقف عن استخدام عقار ساندوستاتين إل إيه آر ما لم يخبرك طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الممرض(ة) أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعض الأعراض الجانبية قد تكون خطيرة. أخبر طبيبك على الفور إذا تعرضت لأي مما يلي:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا </strong>(قد تُؤثر على أكثر من 1 من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصى المرارة، مما يُسبب ألمًا مفاجئًا بالظهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستوى أعلى مما يجب من السكر في الدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نشاط الغدة الدَّرقية (قصور الغدة الدَّرقية) الذي يسبب تغيُّرات في مُعدَّل ضربات القلب أو الشهية والوزن، أو تعبًا، أو شعورًا بالبرودة، أو تورُّمًا في الجزء الأمامي من الرقبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في اختبارات وظائف الغدة الدَّرقية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المرارة، وقد تشمل الأعراض الآتي: ألمًا في الجزء العلوي الأيمن من البطن، وحُمّى، والغثيان، واصفرار الجلد والعينين (يرقان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض شديد في مستوى السكر بالدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في تحمل الجلوكوز.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء ضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠٠ شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عطش، انخفاض إنتاج البول، بول داكن، جلد أحمر جاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة الأخرى</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات فرط الحساسية (الحساسية) ومن بينها الطفح الجلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد أنواع تفاعلات الحساسية (التَّأق) الذي قد يُسبب صعوبة في البلع أو التَّنفس، تورُّمًا ووخزًا، وربما يصاحبه هبوط في ضغط الدَّم مع دوخة أو فقدان الوعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب غدة البنكرياس (التهاب البنكرياس)؛ قد تشمل الأعراض ألمًا مفاجئًا في الجزء العلوي من البطن، والغثيان، والقيء، والإِسْهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد؛ قد تشمل الأعراض اصفرار الجلد والعينين (يرقان)، الغثيان، القيء، فقدان الشهية، شعورًا عامًّا بالتوعك، حكة، بولًا فاتح اللون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى تعداد الصَّفائح الدَّموية في الدَّم؛ قد يُؤدي هذا إلى زيادة النزيف أو التكدُّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور إذا لاحظت أيًّا من الآثار الجانبية المذكورة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية أخرى:</strong></p><p dir="RTL">أخبِر طبيبك أو الصيدلي أو الممرض(ة) الخاص بك إذا لاحظت أيًّا من الآثار الجانبية المُدرَجة أدناه. وتكون هذه عادةً طفيفة وتميل إلى الاختفاء مع تقدم العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا </strong>(قد تُؤثر على أكثر من 1 من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِسْهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ (ريح).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم موضعي بموضع الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور غير مريح بالمعدة بعد الوجبات (عُسْرُ الهَضْم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالامتلاء في المعدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; براز دهني.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; براز ليِّن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّر لون البراز.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّر في اختبارات وظائف الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق بالتَّنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك أو الممرض(ة) أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أُصبت بأية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي أو الممرض(ة). ويشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة.بالإبلاغ عن الآثار الجانبية، يُمكِنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يخزن داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">يحفظ في الثلاجة (عند 2&mdash;8 درجة مئوية). لا تقُم بتجميده.</p><p dir="RTL">يُمكِن أن يُخَزَّن عقار ساندوستاتين إل إيه آر في درجة حرارة أقل من 25 درجة مئوية في يوم الحَقْن.</p><p dir="RTL">لا تقُم بتخزين عقار ساندوستاتين إل إيه آر بعد الإعداد (يجب استخدامه فورًا).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصَّلاحية المدون على الملصق والعبوة الكرتونية بعد كلمة &quot;EXP&quot;.&nbsp; يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدَّواء إذا لاحظت وجود جسيمات أو تغير في لونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك حول كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة الفعالة هي أوكتريوتايد تحتوي الزجاجة الواحدة على 10 مجم، أو 20 مجم، أو 30 مجم أوكتريوتايد (في هيئة أسيتات الأوكتريوتايد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: في المسحوق (الزجاجة): عديد (DL-lactide-co-glycolide) ومانيتول (E421).<br />في مذيب (سرنجة معبأة مسبقًا): صوديوم كارميلوز، مانيتول (E421)، بولوكسامير 188، ماء للحَقْن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">عبوات مفردة تحتوي على زجاجة واحدة تحتوي على 6 مللي لتر، ذات سدادة مطاطية (مطاط البروموبوتيل)، محكمة الغلق بغطاء من الألومنيوم قابل للنزع، وتحتوي على مسحوق لإعداد مُعلَّق للحَقْن، وسرنجة زجاجية عديمة اللون ومعبأة مُسبقًا تحتوي على 3 مللي لتر، مع سدادة أمامية وسدادة مكبس (مطاط الكلوروبوتيل) مع مذيب بمقدار 2 مللي لتر، معبأين معًا في عبوة شريط مغلقة مع موائم زجاجة وإبرة حَقْن آمن.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL">قد لا یتم تسویق جمیع العبوات في دولتك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ‌أ.	تم اعتماد هذه النَّشرة من قبل المملكة المتحدة في في: 12/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sandostatin LAR 30 mg powder and solvent for suspension for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial contains 30 mg octreotide (as octreotide acetate).

Excipients with known effect
Contains less than 1 mmol (23 mg) sodium per vial, that is to say essentially “sodium-free”.

For a full list of excipients, see section 6.1.


For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for suspension for injection. 

Powder: White to white with yellowish tint.
Solvent: Clear, colourless to slightly yellow or brown solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of patients with acromegaly in whom surgery is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Treatment of patients with symptoms associated with functional gastro‑entero‑pancreatic endocrine tumours e.g. carcinoid tumours with features of the carcinoid syndrome (see section&nbsp;5.1).</p><p>&nbsp;</p><p>Treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded.</p><p>&nbsp;</p><p>Treatment of TSH‑secreting pituitary adenomas:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; when secretion has not normalised after surgery and/or radiotherapy;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients in whom surgery is inappropriate;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in irradiated patients, until radiotherapy is effective.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p><em><u>Acromegaly</u></em></p><p>It is recommended to start treatment with the administration of 20&nbsp;mg Sandostatin LAR at 4-week intervals for 3&nbsp;months. Patients on treatment with s.c. Sandostatin can start treatment with Sandostatin LAR the day after the last dose of s.c. Sandostatin. Subsequent dosage adjustment should be based on serum growth hormone (GH) and insulin-like growth factor 1/somatomedin C (IGF‑1) concentrations and clinical symptoms.</p><p>&nbsp;</p><p>For patients in whom, within this 3-month period, clinical symptoms and biochemical parameters (GH; IGF‑1) are not fully controlled (GH concentrations still above 2.5&nbsp;microgram/L), the dose may be increased to 30&nbsp;mg every 4&nbsp;weeks. If after 3&nbsp;months, GH, IGF‑1, and/or symptoms are not adequately controlled at a dose of 30&nbsp;mg, the dose may be increased to 40&nbsp;mg every 4&nbsp;weeks.</p><p>&nbsp;</p><p>For patients whose GH concentrations are consistently below 1&nbsp;microgram/L, whose IGF‑1 serum concentrations normalised, and in whom most reversible signs/symptoms of acromegaly have disappeared after 3&nbsp;months of treatment with 20&nbsp;mg, 10&nbsp;mg Sandostatin LAR may be administered every 4&nbsp;weeks. However, particularly in this group of patients, it is recommended to closely monitor adequate control of serum GH and IGF‑1 concentrations, and clinical signs/symptoms at this low dose of Sandostatin LAR.</p><p>&nbsp;</p><p>For patients on a stable dose of Sandostatin LAR, assessment of GH and IGF‑1 should be made every 6&nbsp;months.</p><p>&nbsp;</p><p><em><u>Gastro‑entero‑pancreatic endocrine tumours</u></em></p><p><em>&nbsp;</em></p><p><em>Treatment of patients with symptoms associated with functional gastro-entero-pancreatic neuroendocrine tumours</em></p><p>It is recommended to start treatment with the administration of 20&nbsp;mg Sandostatin LAR at 4-week intervals. Patients on treatment with s.c. Sandostatin should continue at the previously effective dosage for 2&nbsp;weeks after the first injection of Sandostatin LAR.</p><p>&nbsp;</p><p>For patients in whom symptoms and biological markers are well controlled after 3&nbsp;months of treatment, the dose may be reduced to 10&nbsp;mg Sandostatin LAR every 4&nbsp;weeks.</p><p>&nbsp;</p><p>For patients in whom symptoms are only partially controlled after 3&nbsp;months of treatment, the dose may be increased to 30&nbsp;mg Sandostatin LAR every 4&nbsp;weeks.</p><p>&nbsp;</p><p>For days when symptoms associated with gastro-entero-pancreatic tumours may increase during treatment with Sandostatin LAR, additional administration of s.c. Sandostatin is recommended at the dose used prior to the Sandostatin LAR treatment. This may occur mainly in the first 2&nbsp;months of treatment until therapeutic concentrations of octreotide are reached.</p><p>&nbsp;</p><p><em>Treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded</em></p><p>The recommended dose of Sandostatin LAR is 30&nbsp;mg administered every 4&nbsp;weeks (see section 5.1). Treatment with Sandostatin LAR for tumour control should be continued in the absence of tumour progression.</p><p>&nbsp;</p><p><em><u>Treatment of TSH-secreting adenomas</u></em></p><p>Treatment with Sandostatin LAR should be started at a dose of 20&nbsp;mg at 4-weekly intervals for 3&nbsp;months before considering dose adjustment. The dose is then adjusted on the basis of the TSH and thyroid hormone response.</p><p>&nbsp;</p><p><em><u>Use in patients with impaired renal function</u></em></p><p>Impaired renal function did not affect the total exposure (AUC) to octreotide when administered s.c. as Sandostatin.&nbsp; Therefore, no dose adjustment of Sandostatin LAR is necessary.</p><p>&nbsp;</p><p><em><u>Use in patients with impaired hepatic function</u></em></p><p>&nbsp;In a study with Sandostatin administered s.c. and i.v. it was shown that the elimination capacity may be reduced in patients with liver cirrhosis, but not in patients with fatty liver disease.&nbsp; In certain cases patients with impaired hepatic function may require dose adjustment.</p><p>&nbsp;</p><p><u>Use in the elderly</u></p><p>In a study with Sandostatin administered s.c., no dose adjustment was necessary in subjects <!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt'><span style='mso-element:field-begin'></span>symbol
179 \f &quot;Symbol&quot; \s 12</span><![endif]--><!--[if supportFields]><span
lang=EN-GB style='font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--> 65 years of age.&nbsp; Therefore, no dose adjustment is necessary in this group of patients with Sandostatin LAR.</p><p>&nbsp;</p><p><em><u>Use in children</u></em></p><p>There is limited experience with the use of Sandostatin LAR in children.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Sandostatin LAR may only be administered by deep intramuscular injection.&nbsp; The site of repeat intramuscular injections should be alternated between the left and right gluteal muscle (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Known hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p><strong>&nbsp;</strong></p><p>As GH-secreting pituitary tumours may sometimes expand, causing serious complications (e.g. visual field defects), it is essential that all patients be carefully monitored.&nbsp; If evidence of tumour expansion appears, alternative procedures may be advisable.</p><p>&nbsp;</p><p>The therapeutic benefits of a reduction in growth hormone (GH) levels and normalisation of insulin-like growth factor 1 (IGF-1) concentration in female acromegalic patients could potentially restore fertility.&nbsp; Female patients of childbearing potential should be advised to use adequate contraception if necessary during treatment with octreotide (see section 4.6).</p><p>&nbsp;</p><p>Thyroid function should be monitored in patients receiving prolonged treatment with octreotide.</p><p>&nbsp;</p><p>Hepatic function should be monitored during octreotide therapy.</p><p>&nbsp;</p><p><u>Cardiovascular related events</u></p><p><u>&nbsp;</u></p><p>Common cases of bradycardia have been reported.&nbsp; Dose adjustment of medicinal products such as beta blockers, calcium channel blockers, or agents to control fluid and electrolyte balance, may be necessary (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Gallbladder and related events</u></p><p>&nbsp;</p><p>Cholelithiasis is a very common event during Sandostatin treatment and may be associated with cholecystitis and biliary duct dilatation (see section 4.8). Additionally, cases of cholangitis have been reported as a complication of cholelithiasis in patients taking Sandostatin LAR in the post-marketing setting. Ultrasonic examination of the gallbladder before and at about 6-monthly intervals during Sandostatin LAR therapy is recommended.&nbsp;</p><p>&nbsp;</p><p><u>Glucose metabolism</u></p><p>&nbsp;</p><p>Because of its inhibitory action on growth hormone, glucagon, and insulin release, Sandostatin LAR may affect glucose regulation.&nbsp; Post-prandial glucose tolerance may be impaired.&nbsp; As reported for patients treated with s.c. Sandostatin, in some instances, the state of persistent hyperglycaemia may be induced as a result of chronic administration.&nbsp; Hypoglycaemia has also been reported.</p><p>&nbsp;</p><p>In patients with concomitant Type I diabetes mellitus, Sandostatin LAR is likely to affect glucose regulation, and insulin requirements may be reduced.&nbsp; In non-diabetics and type II diabetics with partially intact insulin reserves, Sandostatin s.c. administration may result in increases in post-prandial glycaemia.&nbsp; It is therefore recommended to monitor glucose tolerance and antidiabetic treatment.</p><p>&nbsp;</p><p>In patients with insulinomas, octreotide, because of its greater relative potency in inhibiting the secretion of GH and glucagon than that of insulin, and because of the shorter duration of its inhibitory action on insulin, may increase the depth and prolong the duration of hypoglycaemia.&nbsp; These patients should be closely monitored.</p><p>&nbsp;</p><p><u>Nutrition</u></p><p><strong><u>&nbsp;</u></strong></p><p>Octreotide may alter absorption of dietary fats in some patients.</p><p>&nbsp;</p><p>Depressed vitamin B12 levels and abnormal Schilling&rsquo;s tests have been observed in some patients receiving octreotide therapy.&nbsp; Monitoring of vitamin B12 levels is recommended during therapy with Sandostatin LAR in patients who have a history of vitamin B12 deprivation.</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>&nbsp;</p><p>Sandostatin LAR contains less than 1&nbsp;mmol (23&nbsp;mg) sodium per vial, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dose adjustment of medicinal products such as beta blockers, calcium channel blockers, or agents to control fluid and electrolyte balance may be necessary when Sandostatin LAR is administered concomitantly (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Dose adjustments of insulin and antidiabetic medicinal products may be required when Sandostatin LAR is administered concomitantly (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Octreotide has been found to reduce the intestinal absorption of ciclosporin and to delay that of cimetidine.</p><p>&nbsp;</p><p>Concomitant administration of octreotide and bromocriptine increases the bioavailability of bromocriptine.</p><p>&nbsp;</p><p>Limited published data indicate that somatostatin analogues might decrease the metabolic clearance of compounds known to be metabolised by cytochrome P450 enzymes, which may be due to the suppression of growth hormone.&nbsp; Since it cannot be excluded that octreotide may have this effect, other drugs mainly metabolised by CYP3A4 and which have a low therapeutic index (e.g. quinidine, terfenadine) should therefore be used with caution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There is a limited amount of data (less than 300&nbsp;pregnancy outcomes) from the use of octreotide in pregnant women, and in approximately one third of the cases the pregnancy outcomes are unknown. The majority of reports were received after post-marketing use of octreotide and more than 50% of exposed pregnancies were reported in patients with acromegaly. Most women were exposed to octreotide during the first trimester of pregnancy at doses ranging from 100‑1200&nbsp;micrograms/day of Sandostatin s.c. or 10‑40&nbsp;mg/month of Sandostatin LAR. Congenital anomalies were reported in about 4% of pregnancy cases for which the outcome is known. No causal relationship to octreotide is suspected for these cases.</p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section&nbsp;5.3).</p><p>&nbsp;</p><p>As a precautionary measure, it is preferable to avoid the use of Sandostatin LAR during pregnancy (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p><strong><u>&nbsp;</u></strong></p><p>It is unknown whether octreotide is excreted in human breast milk.&nbsp; Animal studies have shown excretion of octreotide in breast milk.&nbsp; Patients should not breast-feed during Sandostatin LAR treatment.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>It is not known whether octreotide has an effect on human fertility. Late descent of the testes was found for male offsprings of dams treated during pregnancy and lactation. Octreotide, however, did not impair fertility in male and female rats at doses of up to 1&nbsp;mg/kg body weight per day (see section&nbsp;5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sandostatin LAR has no or negligible influence on the ability to drive and use machines. Patients should be advised to be cautious when driving or using machines if they experience dizziness, asthenia/fatigue, or headache during treatment with Sandostatin LAR.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>a.Summary of the safety profile</u></p><p>&nbsp;</p><p>The most frequent adverse reactions reported during octreotide therapy include gastrointestinal disorders, nervous system disorders, hepatobiliary disorders, and metabolism and nutritional disorders.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions in clinical trials with octreotide administration were diarrhoea, abdominal pain, nausea, flatulence, headache, cholelithiasis, hyperglycaemia and constipation.&nbsp; Other commonly reported adverse reactions were dizziness, localised pain, biliary sludge, thyroid dysfunction (e.g., decreased thyroid stimulating hormone [TSH], decreased total T4, and decreased free T4), loose stools, impaired glucose tolerance, vomiting, asthenia, and hypoglycaemia.</p><p>&nbsp;</p><p><u>b.Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The following adverse drug reactions, listed in Table 1, have been accumulated from clinical studies with octreotide:</p><p>&nbsp;</p><p>Adverse drug reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common (&ge;1/10); common (&ge;1/100, &lt;1/10); uncommon (&ge;1/1,000, &lt;1/100); rare (&ge;1/10,000, &lt;1/1,000) very rare (&lt;1/10,000), including isolated reports.&nbsp; Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Table 1</strong><strong> &nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Adverse drug reactions reported in clinical studies</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:91%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Diarrhoea, abdominal pain, nausea, constipation, flatulence.</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dyspepsia, vomiting, abdominal bloating, steatorrhoea, loose stools, discolouration of faeces.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Headache.</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dizziness.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Hypothyroidism, thyroid disorder (e.g., decreased TSH, decreased total T4, and decreased free T4).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Cholelithiasis.</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Cholecystitis, biliary sludge, hyperbilirubinaemia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Hyperglycaemia.</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Hypoglycaemia, impaired glucose tolerance, anorexia.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dehydration.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Injection site reactions.</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Asthenia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Elevated transaminase levels.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Pruritus, rash, alopecia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dyspnoea.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Bradycardia.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Tachycardia.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Post-marketing</u></p><p>Spontaneously reported adverse reactions, presented in Table 2, are reported voluntarily and it is not always possible to reliably establish frequency or a causal relationship to drug exposure.</p><p>&nbsp;</p><p><strong>Table 2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse drug reactions derived from spontaneous reports</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anaphylaxis, allergy/hypersensitivity reactions.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Acute pancreatitis, acute hepatitis without cholestasis, cholestatic hepatitis, cholestasis, jaundice, cholestatic jaundice.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmias.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increased alkaline phosphatase levels, increased gamma glutamyl transferase levels.</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>c.Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Gallbladder and related reactions</em></p><p>Somatostatin analogues have been shown to inhibit gallbladder contractility and decrease bile secretion, which may lead to gallbladder abnormalities or sludge. Development of gallstones has been reported in 15 to 30% of long-term recipients of s.c. Sandostatin. The incidence in the general population (aged 40 to 60 years) is about 5 to 20%. Long-term exposure to Sandostatin LAR of patients with acromegaly or gastro-entero-pancreatic tumors suggests that treatment with Sandostatin LAR does not increase the incidence of gallstone formation, compared with s.c. treatment. If gallstones do occur, they are usually asymptomatic; symptomatic stones should be treated either by dissolution therapy with bile acids or by surgery.</p><p>&nbsp;</p><p><em>Gastrointestinal disorders</em></p><p>In rare instances, gastrointestinal side effects may resemble acute intestinal obstruction, with progressive abdominal distension, severe epigastric pain, abdominal tenderness and guarding.</p><p>&nbsp;</p><p>The frequency of gastrointestinal adverse events is known to decrease over time with continued treatment.</p><p>&nbsp;</p><p><em>Hypersensitivity and anaphylactic reactions</em></p><p>Hypersensitivity and allergic reactions have been reported during post-marketing. When these occur, they mostly affect the skin, rarely the mouth and airways. Isolated cases of anaphylactic shock have been reported.</p><p>&nbsp;</p><p><em>Injection site reactions</em></p><p>Injection site related reactions including pain, redness, haemorrhage, pruritus, swelling or induration were commonly reported in patients receiving Sandostatin LAR; however, these events did not require any clinical intervention in the majority of the cases.</p><p>&nbsp;</p><p><em>Metabolism and nutrition disorders</em></p><p>Although measured faecal fat excretion may increase, there is no evidence to date that long-term treatment with octreotide has led to nutritional deficiency due to malabsorption.</p><p>&nbsp;</p><p><em>Pancreatic enzymes</em></p><p>In very rare instances, acute pancreatitis has been reported within the first hours or days of Sandostatin s.c. treatment and resolved on withdrawal of the drug. In addition, cholelithiasis-induced pancreatitis has been reported for patients on long‑term Sandostatin s.c. treatment.</p><p>&nbsp;</p><p><em>Cardiac disorders</em></p><p>Bradycardia is a common adverse reaction with somatostatin analogues. In both acromegalic and carcinoid syndrome patients, ECG changes were observed such as QT prolongation, axis shifts, early repolarisation, low voltage, R/S transition, early R wave progression, and non‑specific ST‑T wave changes. The relationship of these events to octreotide acetate is not established because many of these patients have underlying cardiac diseases (see section 4.4).</p><p>&nbsp;</p><p><em>Thrombocytopenia</em></p><p>Thrombocytopenia has been reported during post-marketing experience, particularly during treatment with Sandostatin (i.v.) in patients with cirrhosis of the liver, and during treatment with Sandostatin LAR. This is reversible after discontinuation of treatment.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A limited number of accidental overdoses of Sandostatin LAR have been reported.&nbsp; The doses ranged from 100 mg to 163 mg/month of Sandostatin LAR.&nbsp; The only adverse event reported was hot flushes.</p><p>&nbsp;</p><p>Cancer patients receiving doses of Sandostatin LAR up to 60 mg/month and up to 90 mg/2 weeks have been reported.&nbsp; These doses were in general well tolerated; however, the following adverse events have been reported: frequent urination, fatigue, depression, anxiety, and lack of concentration.</p><p>&nbsp;</p><p>The management of overdosage is symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Somatostatin and analogues, ATC code: H01CB02</p><p>&nbsp;</p><p>Octreotide is a synthetic octapeptide derivative of naturally occurring somatostatin with similar pharmacological effects, but with a considerably prolonged duration of action.&nbsp; It inhibits pathologically increased secretion of growth hormone (GH) and of peptides and serotonin produced within the GEP endocrine system.</p><p>&nbsp;</p><p>In animals, octreotide is a more potent inhibitor of GH, glucagon and insulin release than somatostatin is, with greater selectivity for GH and glucagon suppression.</p><p>In healthy subjects octreotide, like somatostatin, has been shown to inhibit:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; release of GH stimulated by arginine, exercise- and insulin-induced hypoglycaemia,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; post-prandial release of insulin, glucagon, gastrin, other peptides of the GEP endocrine system, and arginine-stimulated release of insulin and glucagon,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thyrotropin-releasing hormone (TRH)-stimulated release of thyroid-stimulating hormone (TSH).</p><p>&nbsp;</p><p>Unlike somatostatin, octreotide inhibits GH secretion preferentially over insulin and its administration is not followed by rebound hypersecretion of hormones (i.e. GH in patients with acromegaly).</p><p>&nbsp;</p><p>In patients with acromegaly, Sandostatin LAR, a galenical formulation of octreotide suitable for repeated administration at intervals of 4 weeks, delivers consistent and therapeutic octreotide serum concentrations thus consistently lowering GH and normalising IGF 1 serum concentrations in the majority of patients.&nbsp; In most patients, Sandostatin LAR markedly reduces the clinical symptoms of the disease, such as headache, perspiration, paraesthesia, fatigue, osteoarthralgia and carpal tunnel syndrome.&nbsp; In previously untreated acromegaly patients with GH-secreting pituitary adenoma, Sandostatin LAR treatment resulted in a tumour volume reduction of &gt;20% in a significant proportion (50%) of patients.</p><p>&nbsp;</p><p>In individual patients with GH-secreting pituitary adenoma, Sandostatin LAR was reported to lead to shrinkage of the tumour (prior to surgery).&nbsp; However, surgery should not be delayed.&nbsp;</p><p>&nbsp;</p><p>For patients with functional tumours of the gastro-entero-pancreatic endocrine system, treatment with Sandostatin LAR provides continuous control of symptoms related to the underlying disease.&nbsp; The effect of octreotide in different types of gastro-entero-pancreatic tumours are as follows:</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Carcinoid tumours</u></p><p>&nbsp;</p><p>Administration of octreotide may result in improvement of symptoms, particularly of flushing and diarrhoea.&nbsp; In many cases, this is accompanied by a fall in plasma serotonin and reduced urinary excretion of 5 hydroxyindole acetic acid.</p><p>&nbsp;</p><p><u>VIPomas</u>&nbsp;</p><p>&nbsp;</p><p>The biochemical characteristic of these tumours is overproduction of vasoactive intestinal peptide (VIP).&nbsp; In most cases, administration of octreotide results in alleviation of the severe secretory diarrhoea typical of the condition, with consequent improvement in quality of life.&nbsp; This is accompanied by an improvement in associated electrolyte abnormalities, e.g.&nbsp; hypokalaemia, enabling enteral and parenteral fluid and electrolyte supplementation to be withdrawn. In some patients, computed tomography scanning suggests a slowing or arrest of progression of the tumour, or even tumour shrinkage, particularly of hepatic metastases.&nbsp; Clinical improvement is usually accompanied by a reduction in plasma VIP levels, which may fall into the normal reference range.</p><p>&nbsp;</p><p><u>Glucagonomas </u></p><p>&nbsp;</p><p>Administration of octreotide results in most cases in substantial improvement of the necrolytic migratory rash which is characteristic of the condition.&nbsp; The effect of octreotide on the state of mild diabetes mellitus which frequently occurs is not marked and, in general, does not result in a reduction of requirements for insulin or oral hypoglycaemic agents.&nbsp; Octreotide produces improvement of diarrhoea, and hence weight gain, in those patients affected.&nbsp; Although administration of octreotide often leads to an immediate reduction in plasma glucagon levels, this decrease is generally not maintained over a prolonged period of administration, despite continued symptomatic improvement.</p><p><strong>&nbsp;</strong></p><p><u>Gastrinomas/Zollinger-Ellison syndrome</u></p><p>&nbsp;</p><p>Therapy with proton pump inhibitors or H2 receptor blocking agents generally controls gastric acid hypersecretion. However, diarrhoea, which is also a prominent symptom, may not be adequately alleviated by proton pump inhibitors or H2 receptor blocking agents. Sandostatin LAR can help to further reduce gastric acid hypersecretion and improve symptoms, including diarrhoea, as it provides suppression of elevated gastrin levels, in some patients.</p><p>&nbsp;</p><p><u>Insulinomas</u></p><p>&nbsp;</p><p>Administration of octreotide produces a fall in circulating immunoreactive insulin. In patients with operable tumours, octreotide may help to restore and maintain normoglycemia pre-operatively. In patients with inoperative benign or malignant tumours, glycaemic control may be improved even without concomitant sustained reduction in circulating insulin levels.</p><p><strong>&nbsp;</strong></p><p><u>Advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded</u></p><p><strong><em>&nbsp;</em></strong></p><p>A Phase III, randomised, double-blind, placebo-controlled study (PROMID) demonstrated that Sandostatin LAR inhibits tumour growth in patients with advanced neuroendocrine tumours of the midgut. &nbsp;85 patients were randomised to receive Sandostatin LAR 30 mg every 4 weeks (n=42) or placebo (n=43) for 18 months, or until tumour progression or death.</p><p>&nbsp;</p><p>Main inclusion criteria were: treatment na&iuml;ve; histologically confirmed; locally inoperable or metastatic well-differentiated; functionally active or inactive neuroendocrine tumours/carcinomas; with primary tumour located in the midgut or unknown origin believed to be of midgut origin if a primary within the pancreas, chest, or elsewhere was excluded.</p><p>&nbsp;</p><p>The primary endpoint was time to tumour progression or tumour-related death (TTP).</p><p>&nbsp;</p><p>In the intent-to-treat analysis population (ITT) (all randomised patients), 26 and 41&nbsp;progressions or tumour-related deaths were seen in the Sandostatin LAR and placebo groups, respectively (HR = 0.32; 95% CI, 0.19 to 0.55; p-value =.000015).</p><p>&nbsp;</p><p>In the conservative ITT (cITT) analysis population in which 3&nbsp;patients were censored at randomization, 26 and 40&nbsp;progressions or tumour-related deaths were observed in the Sandostatin LAR and placebo groups, respectively (HR=0.34; 95% CI, 0.20 to 0.59; p-value =.000072; Fig&nbsp;1). Median time to tumour progression was 14.3&nbsp;months (95% CI, 11.0 to 28.8 months) in the Sandostatin LAR group and 6.0&nbsp;months (95% CI, 3.7 to 9.4&nbsp;months) in the placebo group.</p><p>&nbsp;</p><p>In the per-protocol analysis population (PP) in which additional patients were censored at end study therapy, tumour progression or tumour-related death was observed in 19 and 38&nbsp;Sandostatin LAR and placebo recipients, respectively (HR = 0.24; 95% CI, 0.13 to 0.45; p-value =.0000036).</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Figure 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier estimates of TTP comparing Sandostatin LAR with placebo (conservative ITT population)</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_5" o:spid="_x0000_s1026" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:391.65pt;
 margin-top:-42.7pt;width:442.85pt;height:272.4pt;z-index:251657728;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:right;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page'>
 <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--><img width="590" height="363" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg" />&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>Table 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TTP results by analysis populations</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>TTP Events</p></td><td colspan="2" style="vertical-align:top"><p>Median TTP months [95% C.I.]</p></td><td rowspan="2" style="vertical-align:top"><p>HR [95% C.I.]</p><p>p-value *</p></td></tr><tr><td style="vertical-align:top"><p>Sandostatin LAR</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Sandostatin LAR</p></td><td style="vertical-align:top"><p>Placebo</p></td></tr><tr><td style="vertical-align:top"><p>ITT</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>0.32</p><p>[95% CI, 0.19 to 0.55] P=0.000015</p></td></tr><tr><td style="vertical-align:top"><p>cITT</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>14.3</p><p>[95% CI, 11.0 to 28.8]</p></td><td style="vertical-align:top"><p>6.0</p><p>[95% CI, 3.7 to 9.4]</p></td><td style="vertical-align:top"><p>0.34</p><p>[95% CI, 0.20 to 0.59] P=0.000072</p></td></tr><tr><td style="vertical-align:top"><p>PP</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>0.24</p><p>[95% CI, 0.13 to 0.45] P=0.0000036</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>NR=not reported; HR=hazard ratio; TTP=time to tumour progression; ITT=intention to treat; cITT=conservative ITT; PP=per protocol</p><p>*Logrank test stratified by functional activity</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Treatment effect was similar in patients with functionally active (HR = 0.23; 95% CI, 0.09 to 0.57) and inactive tumours (HR = 0.25; 95% CI, 0.10 to 0.59).</p><p>&nbsp;</p><p>After 6&nbsp;months of treatment, stable disease was observed in 67% of patients in the Sandostatin LAR group and 37% of patients in the placebo group.</p><p><strong>&nbsp;</strong></p><p>Based on the significant clinical benefit of Sandostatin LAR observed in this pre-planned interim analysis the recruitment was stopped.</p><p>&nbsp;</p><p>The safety of Sandostatin LAR in this trial was consistent with its established safety profile.</p><p>&nbsp;</p><p><u>Treatment of TSH‑secreting pituitary adenomas </u></p><p><u>&nbsp;</u></p><p>Sandostatin LAR, one i.m. injection every 4&nbsp;weeks, has been shown to suppress elevated thyroid hormones, to normalise TSH and to improve the clinical signs and symptoms of hyperthyroidism in patients with TSH-secreting adenomas. Treatment effect of Sandostatin LAR reached statistical significance as compared to baseline after 28&nbsp;days and treatment benefit continued for up to 6&nbsp;months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After single i.m. injections of Sandostatin LAR, the serum octreotide concentration reaches a transient initial peak within 1 hour after administration, followed by a progressive decrease to a low undetectable octreotide level within 24 hours.&nbsp; After this initial peak on day 1, octreotide remains at sub-therapeutic levels in the majority of the patients for the following 7 days.&nbsp; Thereafter, octreotide concentrations increase again, and reach plateau concentrations around day 14 and remain relatively constant during the following 3 to 4 weeks.&nbsp; The peak level during day 1 is lower than levels during the plateau phase and no more than 0.5% of the total drug release occurs during day 1.&nbsp; After about day 42, the octreotide concentration decreases slowly, concomitant with the terminal degradation phase of the polymer matrix of the dosage form.</p><p>&nbsp;</p><p>In patients with acromegaly, plateau octreotide concentrations after single doses of 10 mg, 20 mg and 30 mg Sandostatin LAR amount to 358 ng/L, 926 ng/L, and 1,710 ng/L, respectively.&nbsp; Steady-state octreotide serum concentrations, reached after 3 injections at 4 week intervals, are higher by a factor of approximately 1.6 to 1.8 and amount to 1,557 ng/L and 2,384 ng/L after multiple injections of 20 mg and 30 mg Sandostatin LAR, respectively.</p><p>&nbsp;</p><p>In patients with carcinoid tumours, the mean (and median) steady-state serum concentrations of octreotide after multiple injections of 10 mg, 20 mg and 30 mg of Sandostatin LAR given at 4 week intervals also increased linearly with dose and were 1,231 (894) ng/L, 2,620 (2,270) ng/L and 3,928 (3,010) ng/L, respectively.</p><p>&nbsp;</p><p>No accumulation of octreotide beyond that expected from overlapping release profiles occurred over a duration of up to 28 monthly injections of Sandostatin LAR.</p><p>&nbsp;</p><p>The pharmacokinetic profile of octreotide after injection of Sandostatin LAR reflects the release profile from the polymer matrix and its biodegradation.&nbsp; Once released into the systemic circulation, octreotide distributes according to its known pharmacokinetic properties, as described for s.c. administration.&nbsp; The volume of distribution of octreotide at steady-state is 0.27 L/kg and the total body clearance is 160 mL/min.&nbsp; Plasma protein binding amounts to 65% and essentially no drug is bound to blood cells.</p><p>&nbsp;</p><p>Pharmacokinetic data with limited blood sampling in pediatric patients with hypothalamic obesity, aged 7&ndash;17 years, receiving Sandostatin LAR 40 mg once monthly, showed&nbsp;mean octreotide trough plasma concentrations of 1,395 ng/L after the first injection and of 2,973 ng/L at steady state. A high inter-subject variability is observed.</p><p>&nbsp;</p><p>Steady-state trough octreotide concentrations were not correlated with age and BMI, but moderately correlated with body weight (52.3&ndash;133 kg) and was significantly different between male and female patients, i.e. about 17% higher for female patients.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute and repeated dose toxicology, genotoxicity, carcinogenicity and reproductive toxicology studies in animals revealed no specific safety concerns for humans.</p><p>&nbsp;</p><p>Reproduction studies in animals revealed no evidence of teratogenic, embryo/foetal or other reproduction effects due to octreotide at parental doses of up to 1&nbsp;mg/kg/day. Some retardation of the physiological growth was noted in the offspring of rats which was transient and attributable to GH inhibition brought about by excessive pharmacodynamic activity (see section&nbsp;4.6).</p><p>&nbsp;</p><p>No specific studies were conducted in juvenile rats. In the pre- and post-natal developmental studies, reduced growth and maturation was observed in the F1 offspring of dams given octreotide during the entire pregnancy and lactation period. Delayed descent of the testes was observed for male F1 offsprings, but fertility of the affected F1 male pups remained normal. Thus, the above mentioned observations were transient and considered to be the consequence of GH inhibition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder (Vial):</p><p>Poly (DL-lactide-co-glycolide)</p><p>Mannitol (E421)</p><p>&nbsp;</p><p>Solvent (Prefilled syringe):</p><p>Carmellose sodium</p><p>Mannitol (E421)</p><p>Poloxamer&nbsp;188</p><p>Water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
The product must not be stored after reconstitution (must be used immediately).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from light.</p><p>Store in a refrigerator (2&deg;C to 8&deg;C). Do not freeze.</p><p>Sandostatin LAR may be stored below 25&deg;C on the day of the injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unit packs containing one 6 mL glass vial with rubber stopper (bromobutyl rubber), sealed with an aluminium flip-off seal, containing powder for suspension for injection and one 3 mL colourless pre-filled glass syringe with front and plunger stopper (chlorobutyl rubber) with 2 mL solvent, co-packaged in a sealed blister tray with one vial adapter and one safety injection needle.</p><p>&nbsp;</p><p>Multipacks of three unit packs, each unit pack containing: one 6&nbsp;mL glass vial with rubber stopper (bromobutyl rubber), sealed with an aluminium flip-off seal, containing powder for suspension for injection and one 3&nbsp;mL colourless pre-filled glass syringe with front and plunger stopper (chlorobutyl rubber) with 2&nbsp;mL solvent, co-packaged in a sealed blister tray with one vial adapter and one safety injection needle.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><strong><u>Instructions for preparation and </u></strong><strong><u>intramuscular injection for</u></strong> <strong><u>Sandostatin LAR</u></strong></p><p>&nbsp;</p><p>FOR DEEP INTRAMUSCULAR INJECTION ONLY</p><p><strong>&nbsp;</strong></p><p><strong>Included in the injection kit:</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:0px"><thead><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shapetype
    id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
    path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
    <v:stroke joinstyle="miter"/>
    <v:formulas>
     <v:f eqn="if lineDrawn pixelLineWidth 0"/>
     <v:f eqn="sum @0 1 0"/>
     <v:f eqn="sum 0 0 @1"/>
     <v:f eqn="prod @2 1 2"/>
     <v:f eqn="prod @3 21600 pixelWidth"/>
     <v:f eqn="prod @3 21600 pixelHeight"/>
     <v:f eqn="sum @0 0 1"/>
     <v:f eqn="prod @6 1 2"/>
     <v:f eqn="prod @7 21600 pixelWidth"/>
     <v:f eqn="sum @8 21600 0"/>
     <v:f eqn="prod @7 21600 pixelHeight"/>
     <v:f eqn="sum @10 21600 0"/>
    </v:formulas>
    <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
    <o:lock v:ext="edit" aspectratio="t"/>
   </v:shapetype><v:shape id="Grafik_x0020_20" o:spid="_x0000_i1040" type="#_x0000_t75"
    style='width:453pt;height:159pt;visibility:visible;mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.wmz"
     o:title=""/>
   </v:shape><![endif]--><img width="604" height="212" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" /></p></td></tr></thead></table><p>a. &nbsp;&nbsp;&nbsp; One vial containing Sandostatin LAR powder,</p><p>b.&nbsp;&nbsp;&nbsp; One prefilled syringe containing the vehicle solution for reconstitution,</p><p>c.&nbsp;&nbsp;&nbsp; One vial adapter for drug product reconstitution,</p><p>d.&nbsp;&nbsp;&nbsp; One safety injection needle.</p><p>&nbsp;</p><p>Follow the instructions below carefully to ensure proper reconstitution of Sandostatin LAR before deep intramuscular injection.</p><p>There are 3&nbsp;critical actions in the reconstitution of Sandostatin LAR. <strong><u>Not following them could result in failure to deliver the drug appropriately.</u></strong></p><ul><li><strong><u>The injection kit must reach room temperature</u></strong>. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30&nbsp;minutes before reconstitution, but do not exceed 24&nbsp;hours.</li><li>After adding the diluent solution, <strong>ensure that the powder is fully saturated</strong> by letting the vial stand for 5&nbsp;minutes<strong><u>.</u></strong></li><li>After saturation, <strong><u>shake the vial moderately</u></strong> in a horizontal direction for a minimum of 30&nbsp;seconds <strong><u>until a uniform suspension is formed. </u></strong>The Sandostatin LAR suspension must only be prepared <strong>immediately</strong> before administration.</li></ul><p>&nbsp;</p><p>Sandostatin LAR should only be administered by a trained healthcare professional.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:0px"><thead><tr><td style="vertical-align:top"><p><strong>Step</strong>&nbsp;<strong>1</strong></p><ul><li>Remove the Sandostatin LAR injection kit from refrigerated storage.</li></ul><p><strong>ATTENTION: It is essential to start the reconstitution process only after the injection kit reaches room temperature. Let the kit stand at room temperature for a minimum of 30</strong>&nbsp;<strong>minutes before reconstitution, but do not exceed 24</strong>&nbsp;<strong>hours.</strong></p><p>Note: The injection kit can be re-refrigerated if needed.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
    id="Grafik_x0020_19" o:spid="_x0000_i1039" type="#_x0000_t75" style='width:109.5pt;
    height:109.5pt;visibility:visible;mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png"
     o:title=""/>
   </v:shape><![endif]--><img width="146" height="146" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.jpg" /></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Step</strong>&nbsp;<strong>2</strong></p><ul><li>Remove the plastic cap from the vial and clean the rubber stopper of the vial with an alcohol wipe.</li><li>Remove the lid film of the vial adapter packaging, but do NOT remove the vial adapter from its packaging.</li><li>Holding the vial adapter packaging, position the vial adapter on top of the vial and push it fully down so that it snaps in place, confirmed by an audible &ldquo;click.&rdquo;</li><li>Lift the packaging off the vial adapter with a vertical movement.</li></ul></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
    id="Grafik_x0020_18" o:spid="_x0000_i1038" type="#_x0000_t75" style='width:149.25pt;
    height:112.5pt;visibility:visible;mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.emz"
     o:title=""/>
   </v:shape><![endif]--><img width="199" height="150" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.gif" /></p><p><!--[if gte vml 1]><v:shape
    id="Grafik_x0020_17" o:spid="_x0000_i1037" type="#_x0000_t75" style='width:154.5pt;
    height:114pt;visibility:visible;mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image007.emz"
     o:title=""/>
   </v:shape><![endif]--><img width="206" height="152" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image008.gif" /></p><p><!--[if gte vml 1]><v:shape
    id="Grafik_x0020_16" o:spid="_x0000_i1036" type="#_x0000_t75" style='width:154.5pt;
    height:114pt;visibility:visible;mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image009.emz"
     o:title=""/>
   </v:shape><![endif]--><img width="206" height="152" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image010.gif" /></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Step</strong>&nbsp;<strong>3</strong></p><ul><li>Remove the cap from the syringe prefilled with diluent solution and screw the syringe onto the vial adapter.</li><li>Slowly push the plunger all the way down to transfer all the diluent solution in the vial.</li></ul><p>&nbsp;</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
    id="Grafik_x0020_15" o:spid="_x0000_i1035" type="#_x0000_t75" style='width:153pt;
    height:115.5pt;visibility:visible;mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image011.emz"
     o:title=""/>
   </v:shape><![endif]--><img width="204" height="154" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image012.gif" /></p><p><!--[if gte vml 1]><v:shape
    id="Grafik_x0020_14" o:spid="_x0000_i1034" type="#_x0000_t75" style='width:153pt;
    height:115.5pt;visibility:visible;mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image013.emz"
     o:title=""/>
   </v:shape><![endif]--><img width="204" height="154" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image014.gif" /></p></td></tr><tr><td style="vertical-align:top"><p><strong>Step</strong>&nbsp;<strong>4</strong></p><p><strong>ATTENTION: It is essential to let the vial stand for 5</strong>&nbsp;<strong> minutes </strong>&nbsp;to ensure that the diluent has fully saturated the powder.</p><p>Note: It is normal if the plunger rod moves up as there might be a slight overpressure in the vial.</p><ul><li>At this stage prepare the patient for injection.</li></ul></td><td style="vertical-align:top"><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
    id="Grafik_x0020_13" o:spid="_x0000_i1033" type="#_x0000_t75" style='width:129.75pt;
    height:99pt;visibility:visible;mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image015.png"
     o:title=""/>
   </v:shape><![endif]--><img width="173" height="132" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image016.jpg" /></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Step</strong>&nbsp;<strong>5</strong></p><ul><li>After the saturation period, make sure that the plunger is pushed all the way down in the syringe.</li></ul><p><strong>ATTENTION</strong>: Keep the plunger pressed and shake the vial <strong>moderately</strong> in a horizontal direction <strong>for a minimum of 30</strong>&nbsp;<strong>seconds </strong>so that the powder is completely suspended (milky uniform suspension). <strong>Repeat moderate shaking for another 30 seconds if the powder is not completely suspended.</strong></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
    id="Grafik_x0020_12" o:spid="_x0000_i1032" type="#_x0000_t75" style='width:146.25pt;
    height:107.25pt;visibility:visible;mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image017.emz"
     o:title=""/>
   </v:shape><![endif]--><img width="195" height="143" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image018.gif" /></p></td></tr><tr><td style="vertical-align:top"><p><strong>Step</strong>&nbsp;<strong>6 </strong></p><ul><li>Turn syringe and vial upside down, slowly pull the plunger back and draw the entire contents from the vial into the syringe.</li><li>Unscrew the syringe from the vial adapter.</li></ul></td><td style="vertical-align:top"><p>&nbsp;<!--[if gte vml 1]><v:shape id="Grafik_x0020_11"
    o:spid="_x0000_i1031" type="#_x0000_t75" style='width:151.5pt;height:112.5pt;
    visibility:visible;mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image019.emz"
     o:title=""/>
   </v:shape><![endif]--><img width="202" height="150" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image020.gif" /></p><p>&nbsp;<!--[if gte vml 1]><v:shape
    id="Grafik_x0020_10" o:spid="_x0000_i1030" type="#_x0000_t75" style='width:151.5pt;
    height:111.75pt;visibility:visible;mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image021.emz"
     o:title=""/>
   </v:shape><![endif]--><img width="202" height="149" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image022.gif" /></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Step</strong>&nbsp;<strong>7 </strong></p><ul><li>Screw the safety injection needle onto the syringe.</li><li>If immediate administration is delayed, gently re-shake the syringe to ensure a milky uniform suspension</li><li>Prepare injection site with an alcohol wipe.</li><li>Pull the protective cover straight off the needle.</li><li>Gently tap the syringe to remove any visible bubbles and expel them from the syringe.</li><li>Proceed <strong>immediately</strong> to Step&nbsp;8&nbsp;for administration to the patient. Any delay may result in sedimentation.</li></ul></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
    id="Grafik_x0020_9" o:spid="_x0000_i1029" type="#_x0000_t75" style='width:146.25pt;
    height:107.25pt;visibility:visible;mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image023.emz"
     o:title=""/>
   </v:shape><![endif]--><img width="195" height="143" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image024.gif" /></p><p><!--[if gte vml 1]><v:shape
    id="Grafik_x0020_8" o:spid="_x0000_i1028" type="#_x0000_t75" style='width:146.25pt;
    height:107.25pt;visibility:visible;mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image025.emz"
     o:title=""/>
   </v:shape><![endif]--><img width="195" height="143" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image026.gif" /></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Step</strong>&nbsp;<strong>8</strong></p><ul><li>Sandostatin LAR must be given only by deep intramuscular injection, <strong>NEVER</strong> intravenously.</li><li>Insert the needle fully into the left or right gluteus at a 90&ordm; angle to the skin.</li><li>Slowly pull back the plunger to check that no blood vessel has been penetrated (reposition if a blood vessel has been penetrated).</li><li>Depress the plunger with steady pressure until the syringe is empty. Withdraw the needle from the injection site and activate the safety guard (as shown in <strong>Step</strong>&nbsp;<strong>9</strong>).</li></ul></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
    id="Grafik_x0020_7" o:spid="_x0000_i1027" type="#_x0000_t75" style='width:147pt;
    height:105pt;visibility:visible;mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image027.emz"
     o:title=""/>
   </v:shape><![endif]--><img width="196" height="140" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image028.gif" /></p></td></tr><tr><td style="vertical-align:top"><p><strong>Step</strong>&nbsp;<strong>9</strong></p><ul><li>Activate the safety guard over the needle in one of the two methods shown:</li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; either press the hinged section of the safety guard down onto a hard surface (figure A)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or push the hinge forward with your finger (figure B).</p><ul><li>An audible &ldquo;click&rdquo; confirms the proper activation.</li><li>Dispose of syringe immediately (in a sharps container).</li></ul></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
    id="Grafik_x0020_6" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:146.25pt;
    height:109.5pt;visibility:visible;mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image029.emz"
     o:title=""/>
   </v:shape><![endif]--><img width="195" height="146" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image030.gif" />&nbsp;<!--[if gte vml 1]><v:shape id="Grafik_x0020_5" o:spid="_x0000_i1025"
    type="#_x0000_t75" style='width:151.5pt;height:113.25pt;visibility:visible;
    mso-wrap-style:square'>
    <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image031.emz"
     o:title=""/>
   </v:shape><![endif]--><img width="202" height="151" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image032.gif" /></p><p>&nbsp;</p></td></tr></thead></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Approved by MHRA in December 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>